Longevity and AI experts discuss the bottlenecks preventing AI-driven insights from becoming actionable clinical interventions.
While many in the biotechnology sector expressed excitement for faster drug approval timelines, some researchers voiced concerns that critical data review could be missed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results